See more : Exail Technologies (EXA.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Zhejiang Wecome Pharmaceutical Company Limited (300878.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zhejiang Wecome Pharmaceutical Company Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Adit EdTech Acquisition Corp. (ADEX) Income Statement Analysis – Financial Results
- Sunac China Holdings Limited (SCCCF) Income Statement Analysis – Financial Results
- Rogers Communications Inc. (RCI-A.TO) Income Statement Analysis – Financial Results
- Central Plains Environment Protection Co.,Ltd. (000544.SZ) Income Statement Analysis – Financial Results
- Acerinox, S.A. (ACX.VI) Income Statement Analysis – Financial Results
Zhejiang Wecome Pharmaceutical Company Limited (300878.SZ)
About Zhejiang Wecome Pharmaceutical Company Limited
Zhejiang Wecome Pharmaceutical Company Limited engages in the research and development, production, and sale of pharmaceutical products. The company also offers healthcare products, over-the-counter products, and Chinese medicines. It offers products in various forms, including hard capsules, tablets, granules, soft capsules, pills, and other dosage forms. The company was formerly known as Zhejiang Weikang Pharmaceutical Co., Ltd. Zhejiang Wecome Pharmaceutical Company Limited was founded in 2000 and is based in Lishui, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 519.62M | 531.29M | 632.95M | 622.77M | 641.80M | 577.65M | 406.53M | 282.09M | 207.74M | 153.28M | 135.06M |
| Cost of Revenue | 258.36M | 220.10M | 204.38M | 171.42M | 167.77M | 142.30M | 124.37M | 111.03M | 84.89M | 66.02M | 68.74M |
| Gross Profit | 261.26M | 311.19M | 428.58M | 451.35M | 474.03M | 435.35M | 282.16M | 171.06M | 122.86M | 87.26M | 66.32M |
| Gross Profit Ratio | 50.28% | 58.57% | 67.71% | 72.47% | 73.86% | 75.37% | 69.41% | 60.64% | 59.14% | 56.93% | 49.11% |
| Research & Development | 42.80M | 39.32M | 37.02M | 20.41M | 21.16M | 16.40M | 15.83M | 14.36M | 12.93M | 9.68M | 8.55M |
| General & Administrative | 8.21M | 6.93M | 6.48M | 11.89M | -7.91M | -9.46M | -8.18M | 18.70M | 28.65M | 19.96M | 20.63M |
| Selling & Marketing | 126.69M | 191.64M | 269.99M | 268.08M | 291.80M | 290.65M | 142.20M | 56.01M | 34.96M | 26.67M | 17.95M |
| SG&A | 216.40M | 198.57M | 276.47M | 279.97M | 283.89M | 281.19M | 134.03M | 74.71M | 63.61M | 46.64M | 38.58M |
| Other Expenses | 1.45M | -1.70M | 886.02K | -5.65M | 481.65K | 6.76M | 5.66M | 19.01M | -159.94K | -12.93M | -7.46M |
| Operating Expenses | 262.87M | 250.37M | 324.30M | 289.50M | 323.50M | 326.64M | 173.53M | 92.97M | 65.64M | 48.17M | 40.00M |
| Cost & Expenses | 520.63M | 470.46M | 528.68M | 460.92M | 491.27M | 468.94M | 297.90M | 204.00M | 150.53M | 114.18M | 108.73M |
| Interest Income | 1.89M | 2.25M | 5.28M | 5.62M | 2.45M | 707.94K | 1.03M | 217.72K | 0.00 | 824.57K | 0.00 |
| Interest Expense | 9.45M | 5.41M | 2.16M | 253.36K | 2.04M | 4.06M | 200.91K | 133.30K | 0.00 | 0.00 | 1.27M |
| Depreciation & Amortization | 49.25M | 45.00M | 29.91M | 15.91M | 16.98M | 6.91M | 5.14M | 9.70M | 5.20M | 4.29M | 4.01M |
| EBITDA | 53.24M | 113.73M | 132.19M | 174.93M | 165.82M | 111.89M | 116.58M | 94.70M | 62.97M | 42.89M | 30.34M |
| EBITDA Ratio | 10.25% | 21.60% | 21.74% | 28.78% | 25.71% | 21.20% | 30.87% | 34.48% | 29.83% | 29.20% | 22.43% |
| Operating Income | -1.01M | 59.45M | 99.14M | 159.04M | 147.10M | 103.39M | 104.87M | 75.56M | 58.11M | 39.43M | 25.10M |
| Operating Income Ratio | -0.20% | 11.19% | 15.66% | 25.54% | 22.92% | 17.90% | 25.80% | 26.78% | 27.97% | 25.72% | 18.59% |
| Total Other Income/Expenses | -4.77M | 3.70M | 886.02K | -336.91K | 535.95K | 6.35K | 6.37M | 19.01M | -272.49K | -13.82M | -7.46M |
| Income Before Tax | -5.79M | 57.75M | 100.03M | 158.70M | 147.64M | 103.40M | 111.23M | 94.57M | 57.83M | 25.61M | 17.64M |
| Income Before Tax Ratio | -1.11% | 10.87% | 15.80% | 25.48% | 23.00% | 17.90% | 27.36% | 33.52% | 27.84% | 16.71% | 13.06% |
| Income Tax Expense | 398.59K | 12.63M | 3.48M | 23.00M | 21.63M | 15.62M | 16.08M | 13.72M | 7.81M | 6.84M | 3.26M |
| Net Income | -8.04M | 48.81M | 96.50M | 135.82M | 126.01M | 87.78M | 95.16M | 80.85M | 50.02M | 20.72M | 19.75M |
| Net Income Ratio | -1.55% | 9.19% | 15.25% | 21.81% | 19.63% | 15.20% | 23.41% | 28.66% | 24.08% | 13.52% | 14.62% |
| EPS | -0.06 | 0.31 | 0.67 | 0.94 | 0.87 | 0.81 | 0.88 | 0.74 | 0.46 | 0.53 | 0.55 |
| EPS Diluted | -0.06 | 0.31 | 0.67 | 0.94 | 0.87 | 0.81 | 0.88 | 0.74 | 0.46 | 0.53 | 0.55 |
| Weighted Avg Shares Out | 133.98M | 144.79M | 144.79M | 144.79M | 144.79M | 108.96M | 108.41M | 108.61M | 108.49M | 39.38M | 36.00M |
| Weighted Avg Shares Out (Dil) | 133.98M | 144.79M | 144.79M | 144.79M | 144.79M | 108.96M | 108.41M | 108.61M | 108.49M | 39.38M | 36.00M |
Source: https://incomestatements.info
Category: Stock Reports